

# 高雄榮民總醫院

## 胃癌診療指引

2024年03月19日 第一版

胃癌醫療團隊共同擬訂

注意事項：這個診療原則主要作為醫師和其他保健專家診療癌症病人參考之用。假如你是一個癌症病人，直接引用這個診療原則並不恰當，只有你的醫師才能決定給你最恰當的治療。

# 修訂指引

- 本共識參考國家衛生研究院出版之胃癌臨床指引、JGCA和NCCN治療指引及其他參考文獻，於2024.03.19由胃癌團隊成員共同討論後修訂。

# 會議討論

上次會議：2023/02/21

本共識與上一版的差異


上一版	新版
1.治療:化學治療、IHC。 page 4	1.修正為全身性治療、HIPEC，新增NGS評估。 page 4
2.治療:化學治療±標靶治療±免疫治療。 page 5	2.修正為全身性治療。 page 5
3. LN dissection指引。 page 8	3.更新LN dissection指引。 page 8
4. HIPEC indication：≥ T4a page 9	4. HIPEC indication修正為≥ T4a or carcinomatosis。 page 9
5.輔助化療處方:TS-1、UFUR、XO、SOX、DOX、 FLOTFOLOFOX、DS。 page 11	5.輔助化療中刪除FLOT。 page 11
6.三線化療oral Lonsurf。 page 16	6. 二線化療修正為二線後，oral Lonsurf 併入。 page 16
7.標靶治療處方:Trastuzumab、Trastuzumab +cisplatin /Carboplatin + xeloda/5FU、Ramucirumab、 Ramucirumab + Paclitaxel。 page 18	7.標靶治療處方中刪除Trastuzumab+cisplatin/ Carboplatin + xeloda/5FU。 page 18

# 胃腺癌

高雄榮民總醫院  
臨床診療指引

2024年第一版

評估	診斷	治療	追蹤
----	----	----	----




# 胃腺癌

高雄榮民總醫院  
臨床診療指引

2024年第一版

評估	診斷	治療	追蹤
----	----	----	----



分數	ECOG
0	無症狀
1	有症狀，但可以正常活動，對生活無影響
2	可以照顧自己但無法工作，躺在床上的時間 < 50%的工作時間
3	躺在床上的時間 > 50%的工作時間
4	長期完全臥床
5	死亡

附註：  
全身性治療：化學治療 ± 標靶藥物治療 ± 免疫藥物治療

# 胃腺癌


高雄榮民總醫院  
臨床診療指引

2024年第一版

評估	診斷	治療	追蹤
<p>手術結果</p> <ul style="list-style-type: none"> <li>R0切除</li> <li>R1切除</li> <li>R2切除</li> <li>遠端轉移</li> </ul>	<ul style="list-style-type: none"> <li>Tis, T1N0</li> <li>T2, T3, T4 或淋巴轉移</li> <li>化學治療 (±放射治療)</li> <li>化學治療 (±放射治療)</li> </ul>	<ul style="list-style-type: none"> <li>觀察</li> <li>觀察或輔助性化學治療 (±放射治療)</li> <li>見-p5 轉移或復發胃癌</li> </ul>	<ul style="list-style-type: none"> <li>※ GOT/GPT, ALP, Alb, CBC, CEA, CA199 Every 3 months for 2 years Every 6 months for 3-5 years then annually</li> <li>※ CXR Every 6 months for 5 years then annually</li> <li>※ Abdominal Sono Every 6 months for 5 years then as clinically indicated</li> <li>※ Panendoscope Annually for 5 years then as clinically indicated</li> <li>※ Abdominal CT Annually for 5 years then as clinically indicated</li> </ul>

Table-1 術後追蹤建議表

Table-2 手術建議表(1)



### Table-2 手術建議表(2)

Type of Gastrectomy with lymph node dissection		
Gastrectomy	Extent of LN dissection	圖表
Total gastrectomy	D1 :Nos 1-7 D1+:D1+Nos 8a,9,11p D2 :D1+Nos 8a,9,11p,11d,12a For tumor invading the esophagus D2 includes Nos.19,20and 110	
Distal gastrectomy	D1 :Nos 1,3,4sb,4d,5,6,7 D1+:D1+Nos 8a, 9 D2 :D1+Nos 8a,9,11p,12a	
Pylorus-preserving gastrectomy	D1 :Nos 1,3,4sb,4d,6,7 D1+:D1+Nos 8a, 9	
Proximal gastrectomy	D1 :Nos 1,2,3a,4sa,4sb,7 D1+:D1+Nos 8a, 9,11p D2: D1 + Nos. 8a, 9, 11p, 11d	



## Table-3 HIPEC 適應症建議表

### Hyperthermic IntraPeritoneal Chemotherapy (HIPEC)

※Indication :  $\geq$  T4a **or carcinomatosis**

※Regimen 1: (41-42°C for 20-60 minutes )

Cisplatin 90 mg 【IP-1】

Etoposide 90 mg

Mitomycin C 30 mg

Reference :No 4-7/strength of Evidence :Level I

※Regimen 2: (41-42°C for 20-60 minutes)

Paclitaxel 80mg/m<sup>2</sup> 【IP Paclitaxel, high dose】

Reference : No 28/strength of Evidence :Level IIB

Table-4.1 化學治療處方建議表：輔助化療

Adjuvant chemotherapy	Schedule	Reference (No)/ strength of Evidence
<b>TS-1</b> 40-60mg , po, bid ( <b>ACTS-GC trial</b> ) (po 4 weeks on, 2 weeks off/or po 2 weeks on, 1 weeks off) BSA >1.5m <sup>2</sup> : 60mg bid;1.25m <sup>2</sup> -1.5m <sup>2</sup> : 50mg bid;<1.25m <sup>2</sup> : 40mg bid	Q42 d /cycle For 12 months	No.8 / Level I
<b>UFUR</b> 2#, po, bid ( <b>NSAS-GC trial</b> )	For 16 months	No.9 / Level I
<b>Oxaliplatin</b> 130 mg/m <sup>2</sup> , IV,D1 <b>【XO】</b> (CLASSIC trial) <b>Xeloda</b> 2# po QAM,3# po QPM (Day1-14) (825-1000mg/m <sup>2</sup> /次)	Q21 d x 8-12cycles	No.10 / Level I
<b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>【SOX】</b> <b>TS-1</b> 40-60mg , po , bid , D1~14 BSA >1.5m <sup>2</sup> : 60mg/bid ; 1.25-1.5m <sup>2</sup> : 50mg/bid ; <1.25m <sup>2</sup> : 40mg/bid	TS-1(2 weeks on, 1 weeks off) →SOX Q21 d x 8 cycles	No.31 / Level II
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【DOX】</b> <b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 1.25#/m <sup>2</sup> ( 625mg/m <sup>2</sup> ), po, bid , D1~14	Q21d x 8 cycles	No.34 / Level IB

Table-4.1 化學治療處方建議表：輔助化療

Adjuvant chemotherapy	Schedule	Reference (No)/ strength of Evidence
<b>Oxaliplatin</b> 85mg/m <sup>2</sup> , IV, D1 <b>【FOLFOX】</b> <b>Leucovorin</b> 400mg/m <sup>2</sup> , IV, D1 <b>5-FU</b> 400mg/m <sup>2</sup> , IV, D1 , <b>5-FU</b> 2400-3000mg/m <sup>2</sup> , IV, D1-2	Q14d x 8-12cycles	No.36 / Level I
<b>TS-1 + docetaxel</b> *stage III <b>【DS】</b> Docetaxel 40mg/m <sup>2</sup> , IV, D1 TS-1 80-120mg/day , po, bid , D1~14 BSA >1.5m <sup>2</sup> : 60mg/bid ; 1.25- 1.5m <sup>2</sup> : 50mg/bid ; <1.25m <sup>2</sup> : 40mg/bid	Q21d x 8 cycles 1 <sup>st</sup> cycle TS-1 2 <sup>nd</sup> ~7 <sup>th</sup> TS-1+ docetaxel 8 <sup>th</sup> 起TS-1 up to 1year	No.37 / Level I

Table-4.2 化學治療處方建議表：術前輔助化療

Neoadjuvant chemotherapy	Schedule	Reference (No)/ strength of Evidence
<b>Oxaliplatin</b> 130 mg/m <sup>2</sup> , IV,D1 <b>【 XO 】</b> (CLASSIC trial) <b>Xeloda</b> 2# po QAM,3# po QPM (Day1-14) (825-1000mg/m <sup>2</sup> /次)	Q21 d x 8-12cycles	No.10 / Level I
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【DOX】</b> <b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 1.25#/m <sup>2</sup> ( 625mg/m <sup>2</sup> ) PO, D1-14	Q21d x 2-4 cycles	No.34 / Level IB
<b>Taxotere</b> 50mg/m <sup>2</sup> , IV, D1 <b>【FLOT】</b> <b>Oxaliplatin</b> 85mg/m <sup>2</sup> , IV, D1 <b>Leucovorin</b> 200mg/m <sup>2</sup> , IV, D1 <b>5-FU</b> 2600mg/m <sup>2</sup> , IV, D1	Q14d x 4-8 cycles 術前4cycles 術後4cycles	No.35 / Level I
<b>Oxaliplatin</b> 85mg/m <sup>2</sup> , IV, D1 <b>【FOLFOX】</b> <b>Leucovorin</b> 400mg/m <sup>2</sup> , IV, D1 <b>5-FU</b> 400mg/m <sup>2</sup> , IV, D1 , <b>5-FU</b> 2400-3000mg/m <sup>2</sup> , IV, D1-2	Q14d /cycle	No.36 / Level I

Table-4.3 化學治療處方建議表：轉移癌

Chemotherapy for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>TS-1</b> 40-60mg , po, bid (吃4周休2周或吃2周休1周) BSA $\geq 1.5\text{m}^2$ : 60mg bid ; $1.25\text{m}^2$ - $1.5\text{m}^2$ : 50mg bid ; $<1.25\text{m}^2$ : 40mg bid	Q42 d /cycle For 12 months	No.8 / Level I
<b>UFUR</b> 2# po bid	For 16 months	No.13 / Level I
<b>Oxaliplatin</b> 130 mg/m <sup>2</sup> , IV,D1 【XO】 (CLASSIC trial) <b>Xeloda</b> 2# po QAM,3# po QPM (Day1-14) (825-1000mg/m <sup>2</sup> /次)	Q21 d x 8- 12cycles	No.10 / Level I
<b>Cisplatin</b> 60-80 mg/m <sup>2</sup> , IV, D1 【FP】 【FP-1】 <b>5-FU</b> 800-1000mg/m <sup>2</sup> , IV, D1-5	Q21 d x 8-12cycles	No.15 / Level II

Table-4.3 化學治療處方建議表：轉移癌

Chemotherapy for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【D-FOX】</b> <b>Oxaliplatin</b> 85mg/m <sup>2</sup> , IV, D1 <b>5-FU</b> 1100mg/m <sup>2</sup> , IV, D1-2	Q14d x 6-8 cycles /Until progression	No.30 /Level II
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【DOX】</b> <b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 1.25#/m <sup>2</sup> ( 625mg/m <sup>2</sup> ) po bid , D1-14	Q21d x 6-8 cycles /Until progression	No.34 /Level IB
<b>Docetaxel</b> 40mg/m <sup>2</sup> , IV, D1 <b>【DS】</b> <b>TS-1</b> 80-120mg/day , po , bid , D1~14	Q21d x 8 cycles/ Until progression	No.37 / Level I
<b>Cisplatin</b> 60mg/m <sup>2</sup> , IV, D8 <b>【SP】</b> <b>TS-1</b> 40-60mg/m <sup>2</sup> , po , bid ( 吃3周休2周)	Q35day/cycle Until progression	No.40 / Level I

Table-4.4 化學治療（二線後）處方建議表

Chemotherapy for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>Irinotecan</b> 150 mg/m <sup>2</sup> , IV, D1	Q14d /cycle Until progression	No.20, 21 /Level I
<b>Docetaxel</b> 60 ~ 75 mg/m <sup>2</sup> , IV, D1	Q21d /cycle Until progression	No.21, 22 /Level I
<b>Paclitaxel</b> 80 mg/m <sup>2</sup> , IV, D1, D8, D15	Q28d/cycle Until progression	No.23 /Level I
<b>Ramucirumab</b> (8 mg/kg , IV, D1, D15) + <b>Paclitaxel</b> (80 mg/m <sup>2</sup> , IV, D1, D8, D15)	Q28d/cycle Until progression	No. 25 /Level I
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV , D1 <b>【D-FOX】</b> <b>Oxaliplatin</b> 85mg/m <sup>2</sup> , IV , D1 <b>5-FU</b> 1100mg/m <sup>2</sup> , IV , D1	Q14d /cycle Until progression	No.30 /Level II

Table-4.4 化學治療（二線後）處方建議表

Chemotherapy for unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>Docetaxel</b> 50mg/m <sup>2</sup> , IV, D1 <b>【DOX】</b> <b>Oxaliplatin</b> 100mg/m <sup>2</sup> , IV, D1 <b>Xeloda</b> 1.25#/m <sup>2</sup> ( 625mg/m <sup>2</sup> ) PO, bid, D1-14	Q21d x 6-8 cycles /Until progression	No.34/Level IB
Oral Lonsurf 35 mg/m <sup>2</sup> , po, bid (D1-5 & D8-12) 前2週服用5天休2天，後2週休息	Q28d/cycle /Until progression	No.38/ Level I



Table-4.5 化學治療 (NIPS) 處方建議表:

NIPS: Neoadjuvant IntraPeritoneal and Systemic chemotherapy  
(Systemic chemotherapy plus intraperitoneal chemotherapy)

Intraperitoneal chemotherapy regimen	Schedule	Reference (No)/ strength of Evidence
Paclitaxel      20mg/m <sup>2</sup> /week      【IP Paclitaxel, low dose】	as clinically indicated	No 27/strength of Evidence :Level IIA

Table-5 標靶治療處方建議表

For unresectable/recurrent disease	Schedule	Reference (No)/ strength of Evidence
<b>Trastuzumab</b> 6-8mg/kg , IV, D1 <b>plus systemic chemotherapy</b> 使用條件： Her-2/neu免疫染色3+, 或2+且FISH positive for amplification	8 mg/kg loading dose, 6 mg/kg every 3 weeks Until progression	No 41 / Level I
<b>Ramucirumab</b> 8 mg/kg, IV, D1	Q14d/cycle Until progression	No. 24 / Level I
<b>Ramucirumab</b> (8 mg/kg, IV, D1, D15) + <b>Paclitaxel</b> (80 mg/m <sup>2</sup> , IV, D1, D8, D15)	Q28d/cycle Until progression	No. 25 /Level I

Table-6 免疫治療處方建議表(免疫治療 + 化學治療)

Nivolumab	3mg/kg	D1	Q2W	Until progression	(Ref. No 32/ Level II)
Pembrolizumab	200mg	D1	Q3W	Until progression	(Ref. No 33/ Level II)

Table-7 放射治療處方建議表

<p>※ <b>Protocol of adjuvant chemoradiotherapy</b></p>	<p>※.For R0 resection <math>\geq</math> stage IIA                  ※ For R1 resection and R2 resection</p>
<p><b>Radiation therapy:</b>                  Target volume: tumor/ gastric bed and pertinent nodal group Dose: 45-50.4 Gy /(1.8 Gy/day)  <b>Chemotherapy regimen:</b>                  5-FU (400 mg/m<sup>2</sup> per day) and leucovorin (20 mg/m<sup>2</sup> per day) on the first four and the last three days of RT. <b>Reference :No 17/strength of Evidence :level 1</b></p>	
<p>※ <b>Protocol of chemoradiation as the primary treatment</b></p>	<p>※ For medically fit patients but unresectable cancer without distant metastasis                  ※ For medically unfit patients without distant metastasis</p>
<p><b>Radiation therapy:</b>                  Target volume: tumor/ gastric bed and pertinent nodal group Dose: 45-50.4 Gy /(1.8 Gy/day)  <b>Chemotherapy regimen:</b>                  5-FU (400 mg/m<sup>2</sup> per day) and leucovorin (20 mg/m<sup>2</sup> per day) on the first four and the last three days of RT. <b>Reference :No 17/strength of Evidence :level 1</b></p>	

## Table-8 癌症藥物停藥準則

影像學檢查，腫瘤有變大或轉移變多，應停止或改變治療方式。

## Reference

1. NCCN Clinical Practice Guideline in Oncology, Gastric cancer , **Version 1.2024**
2. 國家衛生研究院 胃癌臨床診療指引2012年第1版
3. 日本胃癌診療指引2010年第3版
4. Yan TD, Black D, Sugarbaker PH, et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. *Ann Surg Oncol* 2007;14:2702-2713.
5. Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. *Hepatogastroenterol* 2001; 48:1776–82.
6. Deng-Hai Mi , Zheng Li , Ke-Hu Yang et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. *Int J Hyperthermia*. 2013;29(2):156-67
7. Kang LY et al. Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion. *J Chin Med Assoc*. 2013 Aug;76(8):425-31.
8. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med*. 2007;357:1810–20.
9. T.Nakajima,T.Kinoshita,A Nashimoto et al:Randomized controlled trail of adjuvant uracil –tegafur versus surgery alone for serosa –negative ,locally advanced gastric cancer .*British Journal of Surgery* 2007, vol. 94:1468-1476.
10. Sung Hoon Noh, Sook Ryun Park, Han-Kwang Yang et al: Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 2014 Nov;15(12):1389-96
11. K Sumpter,C Harper-Wynne,D cunningham et al:Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.*British journal of Cancer*2005, vol.92:1976-1983.
12. Wasaburo Koizumi,Hiroyuki Narahara,Takuo Hara et al:S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phase III trial . *Lancet oncology* .2008 vol.3.215-221.

13. N.F.Aykan & E.Idlevich:The role of UFT in advanced gastric cancer .Annals of Oncology 2008 ,vol.19.1045-1052.
14. Kim GM, Jeung HC, Rha SY et al. A randomized phase II trial of S-1 oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eu J Cancer* 2012;48:518-526.
15. Park SC and Chun HJ. Chemotherapy for advanced gastric cancer:Review and update of current practices. *Gut and Liver* 2013, vol 7. 385-393.
16. Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al:Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA):a phase 3,open-label,randomised controlled trial.*Lancet*.2012.vol.376.687-697.
17. Macdonald JS; Smalley SR; Benedetti J; Hundahl SA; Estes NC; Stemmermann GN; Haller DG; Ajani JA; Gunderson LL; Jessup JM; Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction [Intergroup trial 0016]. *N Engl J Med* 2001 Sep 6;345(10):725-30.
18. Chikara Kunisaki, MD, PhD, Hirochika Makino, MD, PhD, Jun Kimura, MD et al. Impact of lymphovascular invasion in patients with stage I gastric cancer. *Surgery* 2010;147:204-11.
19. Chunyan Du . Ye Zhou . Kai Huang . Guangfa Zhao . Hong Fu . Yingqiang Shi. Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy. *J Gastrointest Surg*(2011) 15:2153-2158.
20. Peter C. Thuss-Patience et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)*Eur J Cancer*. 2011 Oct;47(15):2306-14
21. Jung Hun Kang et al. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone. *J Clin Oncol* 30:1513-1518; 2012
22. Hugo E R Ford et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *Lancet Oncol* 2014; 15: 78–86.

23. Shuichi Hironaka et al. Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial. *J Clin Oncol* 31:4438-4444; 2013.
24. Charles S Fuchs et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* 2014; 383: 31–39
25. Hansjochen Wilke et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncol* 2014; 15: 1224–35.
26. Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. *Eur J Cancer* 2012;48:518-526.
27. Hironori Yamaguchi et al. Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes. *World Journal of Gastrointestinal Oncology* 2015;7(11):285-291.
28. Motohiro Imano et al, Phase II Study of Single Intraperitoneal Chemotherapy Followed by Systemic Chemotherapy FOR Gastric Cancer with Peritoneal Metastasis. *J Gasyrointest Surg* 2012;16:2190-2196.
29. Manish A. Shah et al, Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. *Journal of clinical oncology* 2015;33:3874-3879.
30. Mariela A. Blum Murphy, MD et al, A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. *American Journal of Clinical Oncology* 2018 ;41:321-325.
31. Kohei Shitara et al, Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy. *Gastric Cancer*. 2015 Dec 20(1) DOI:10.1007/s10120-015-0581-1
32. Yoon-Koo Kang et al, Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet* .2017 Dec 2;390(10111):2461-2471



33. Lola Fashoyin-Aje et al, FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. *Oncologist*.2018 Aug 17 ; 2018-0221
34. E.Van Cutsem et al, Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. *Annals of Oncology* 26: 149–156, 2015.
35. Al-Batran SE et al, Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. *Lancet Oncol*.2016 Dec;17(12):1697-1708.
36. Liu M, Hu G, Wang Y, Guo J, Liu L, Han X, Wang Z, Comparison of FOLFOX and DOF regimens as first-line treatment in East Asian patients with advanced gastric cancer. *OncoTargets and Therapy*.2018;11 Pages 375-381.
37. Kazuhiro Yoshida. et al, Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial . *Journal of Clinical Oncology* 2019;37(15):1296-1304.
38. David H. Ilson, MD, PhD. et al, Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy . *JAMA Oncol*. 2019 Oct 10;6(1):e193531.
39. Japanese gastric cancer treatment guidelines 2018(5th edition). *Gastric Cancer*.2021 Jan;24(1):1-21.
40. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. *Lancet Oncol*. 2008;9:215–21.
41. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). *Gastric Cancer* (2023) 26:1–25